ISSN 2326-7267
International Journal of Pharmacy and Pharmacology ISSN: 2326-7267 Vol. 6 (10), pp. 001-005, October, 2017. © International Scholars Journals
Full Length Research Paper
Cytotoxic evaluation of fluvastatin and rosuvastatin and effect of fluvastatin in the hela cell cycle
María Campos-Lara1 and José Alberto Mendoza-Espinoza2*
1Unidad de Investigación Médica en Farmacología, Centro Médico Nacional Siglo XXI, México City, México.
2Laboratorio de Productos Naturales, Plantel Casa Libertad, Universidad Autónoma de la Ciudad México, Calzada Ermita Iztapalapa Num. 4163, Col. Loma de Zaragoza, 09620 C. P., Delegación Iztapalapa, México City, México D.F., México.
Accepted 13 July, 2017
Abstract
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, were originally designed to reduce cholesterol biosynthesis and have been extensively used as prevention drugs against hyperlipidemia and cardiovascular conditions. Recently, these compounds have been shown to display chemopreventive activity against cancer. However, the effects of statins on cancer are not completely understood. For this reason, we have studied the cytotoxic effect of rosuvastatin and fluvastatin on three cell tumoral lines: human larynx carcinoma (HEp- 2), human nasopharyngeal carcinoma (KB), and human epithelial carcinoma (HeLa). We have found that only fluvastatin has relevant activity against the tumoral cell lines assayed and the capacity to arrest G1- phase, whereas a significant decline was observed in the S-phase percentage. Fluvastatin IC50 were 2.43±0.56 mg/mL (HEp-2), 2.29±0.19 mg/mL (KB), and 5.02±1.52 mg/mL (HeLa), whereas rosuvastatin showed poor activity. These results indicate that the cytotoxic effect of fluvastatin may not depend directly on HMG-CoA reductase inhibition. The antitumor statins effect needs further investigation.
Key words: Cell cycle, cytotoxicity, statins.